MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

CRISPR Therapeutics AG

Chiusa

SettoreSettore sanitario

65.14 18.39

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.04

Massimo

66.28

Metriche Chiave

By Trading Economics

Entrata

-99M

-136M

Vendite

-34M

865K

Margine di Profitto

-15,722.081

Dipendenti

393

EBITDA

-84M

-144M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+26.05% upside

Dividendi

By Dow Jones

Utili prossimi

1 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.6B

4.9B

Apertura precedente

46.75

Chiusura precedente

65.14

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 set 2024, 16:08 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 set 2024, 14:20 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Confronto tra pari

Modifica del prezzo

CRISPR Therapeutics AG Previsione

Obiettivo di Prezzo

By TipRanks

26.05% in crescita

Previsioni per 12 mesi

Media 69.44 USD  26.05%

Alto 105 USD

Basso 35 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CRISPR Therapeutics AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

21 ratings

14

Acquista

7

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

33.5 / 38.27Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

154 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.